MajesTEC-9 randomized 593 patients (median age 70; median two prior lines) to teclistamab or investigator’s choice PVd or Kd; 80% lenalidomide-refractory, 85% anti-CD38–refractory. Interim analysis ...

Accelerating private equity “roll-up” consolidation can evade antitrust thresholds, and post-acquisition staffing reductions have been associated with higher hospital-acquired conditions, falls, ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...

Escalating expenditures in stage ≥3 CKD and especially kidney failure made KRT the predominant cost driver, amplifying value from therapies that delay dialysis or transplantation. Finerenone was ...

Chronic hand eczema is common, heterogeneous, and frequently occupational, with high rates of sick leave, job disruption, and notable annual per-patient societal costs in the United States. Diagnostic ...

FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...

Absence of a scalp-specific cancer excess challenges the UV-exposure hypothesis and supports maintaining standard, individualized skin cancer risk assessment rather than AA-specific screening ...

This article provides a commentary on a news feature published on AJMC.com in 2025 titled “AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds.” We read with interest a feature article ...

This supplement was supported by AstraZeneca. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...